Who Wins in a Walgreens-Amerisource Hookup?
A vertical integration would benefit the no-moat retail pharmacy more than the wide-moat drug distributor.
On Feb. 12, The Wall Street Journal reported that Walgreens (WBA) recently approached AmerisourceBergen (ABC) about acquiring the drug distributor's remaining equity that Walgreens does not already own. This transaction would vertically integrate the drug distribution and retail pharmacy spaces within the U.S. and falls in line with the strategy that Walgreens’ current management team has executed in Europe as it built its Alliance Boots business. While this news is still a press report, we believe the rumor has some substantiation. Over the past few years, Walgreens has partnered and integrated a significant portion of its operating assets and equity with Amerisource. Thus, a total merger seems like the next logical step for the retail pharmacy, particularly given the desire of the firm’s leadership to vertically integrate its business in the U.S. However, we believe Amerisource may not share this sentiment. We have assigned Amerisource a wide moat rating, while we assign Walgreens a no-moat rating, and we believe a vertical integration would benefit Walgreens more than Amerisource. Accordingly, we anticipate Amerisource would demand a significant premium above our $106 fair value estimate. We are leaving our moat ratings and fair value estimates in place, given that there has been no official announcement from either firm regarding a potential merger.
Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.
Vishnu Lekraj does not own shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.